Literature DB >> 9476111

Role of the complement system in pulmonary disorders.

J F Regal1.   

Abstract

Immune injury in the lung is classically divided into types I-IV hypersensitivity, with the complement system being involved in types II and III hypersensitivity. Anaphylaxis and asthma are generally considered prototypes of type I hypersensitivity and hypersensitivity pneumonitis as an example of type III hypersensitivity in the lung. However, in asthma, for example, increasing evidence indicates that in addition to mast cells, T lymphocytes play an important role. Therefore, considering asthma as strictly a type I mediated reaction is too simplistic. This report will review the evidence regarding the involvement of the complement system and complement activation products in anaphylaxis, asthma and immune complex disease in various experimental models of pulmonary disease. Identification of the mediators responsible for the symptoms may suggest rational targets for the continued development of effective therapy to combat immune injury in the lung.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9476111     DOI: 10.1016/s0162-3109(97)00058-1

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  5 in total

1.  Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor.

Authors:  J Sun; J A Ember; T H Chao; Y Fukuoka; R D Ye; T E Hugli
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Trimellitic anhydride-induced eosinophilia in a mouse model of occupational asthma.

Authors:  J F Regal; M E Mohrman; D M Sailstad
Journal:  Toxicol Appl Pharmacol       Date:  2001-09-15       Impact factor: 4.219

3.  Resistance of Mycoplasma pulmonis to complement lysis is dependent on the number of Vsa tandem repeats: shield hypothesis.

Authors:  Warren L Simmons; Amy M Denison; Kevin Dybvig
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 5.  A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation.

Authors:  Marcos A Sanchez-Gonzalez; Dave Moskowitz; Priya D Issuree; George Yatzkan; Syed A A Rizvi; Kenneth Day
Journal:  Infect Chemother       Date:  2020-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.